The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 226.50
Bid: 226.00
Ask: 227.00
Change: 0.50 (0.22%)
Spread: 1.00 (0.442%)
Open: 225.00
High: 229.50
Low: 224.00
Prev. Close: 226.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sonde Launches Voice Health Screening for COVID-19

8 Jul 2020 13:32

RNS Number : 3296S
PureTech Health PLC
08 July 2020
 

8 July 2020

 PureTech Health plc

 

PureTech Founded Entity Sonde Health Launches New Voice-Enabled Health Screening Tool to Potentially Help Employers Return to Work During the Global Pandemic

 

Sonde One combines 6-second voice analysis, CDC-informed COVID-19 questionnaire and body temperature reading in one app

 

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Sonde Health, has launched Sonde One, a new voice-enabled health detection and monitoring app to potentially help employers improve employee safety, meet government mandates and satisfy their own administrative needs as they reopen office doors in a rapidly changing COVID-19 environment.

 

The announcement from Sonde Health is below:

 

Sonde Health Launches New Voice-Enabled Health Screening Tool to Help Employers Return to Work During the Global Pandemic

 

Sonde One combines 6-second voice analysis, COVID-19 questionnaire, and body temperature reading in one app

 

BOSTON-July 8, 2020-As businesses across the country grapple with how to safely bring employees back to the physical workplace, a new voice-enabled health detection and monitoring app from Sonde Health promises to potentially help employers improve employee safety, meet government mandates, and satisfy their own administrative needs as they reopen office doors in a rapidly changing COVID-19 environment.

 

The new tool, called Sonde One, leverages the company's advanced vocal biomarker platform and machine learning technology. With a single 6-second voice sample, the app is designed to quickly and objectively detect respiratory symptoms, such as coughing, shortness of breath, or chest tightness or pain. The app combines this voice analysis with a comprehensive, CDC-informed COVID-19 questionnaire and user inputted body temperature to give employees clear instructions about where they can work within one minute. Employers can deploy the solution to any number of staff anywhere and make daily informed decisions regarding who can go into the workplace or who should work from home, without requiring new equipment or workflows.

 

"At Sonde, we believe that voice is a vital sign and a meaningful predictor of health," said David Liu, Chief Executive Officer for Sonde Health. "By analysing a few seconds of speech, we can detect subtle changes in a person's voice caused by common symptoms of respiratory disease. We built this capability into the Sonde One app so organisations can provide their employees with simple and fast COVID-19 monitoring in their pocket."

 

To bring Sonde One to market, Sonde has partnered with corporate wellness solutions provider Wellworks for You to make the tool available to its clients and their 1.4 million participating members. SHI International, a 5,000-person global provider of technology products and services, is the first enterprise to enrol. The company will begin implementing the Sonde One app in August, as it gradually begins bringing employees back to the workplace, starting with its Somerset, NJ headquarters.

 

"After months of remote work and distributed workforces, many employers want to get their employees back in the office; they're just not sure of the best way to do it," says Thomas Tegler, President of Wellworks for You. "At Wellworks for You, we're always seeking better ways to promote employee wellness and preventative care, and in today's healthcare climate, Sonde Health provides a novel solution. Sonde One is an easy, non-invasive way for organisations to manage employee health risks during the pandemic and potentially get workers back to the office safely."

 

"As we navigate this pandemic, our employees' health and wellness is our top priority," says Michael Haluska, Vice President of Human Resources for SHI International. "From the conference room to the warehouse floor, the Sonde One app will help us standardise our return to work policy to eliminate any confusion and keep all employees feeling safe."

 

Sonde One can be customised to each employer's return to work policy, giving employees clear guidance on whether they should or should not report for physical duty following each screening. Additionally, a QR code can be delivered to employees within the app and scanned at an organisation's front door to confirm compliance with protocols. Secure and customisable reporting capabilities enable employers to confirm employee participation, satisfy enterprise needs, and adhere to mandatory state guidelines surrounding employee screening and documentation.

 

Once an employer signs on, employees can download their employer-specific app via the App Store or Google Play on any smartphone, allowing for fast, simple deployment across enterprises.

 

For more information about Sonde One, visit https://www.sondehealth.com/app-page.

 

About Sonde Health

Leveraging 300,000 voice samples from over 50,000 individuals, Sonde Health's voice-based technology platform is designed to detect health conditions and symptoms from changes in voice. In seconds, Sonde's proprietary technology senses and analyses subtle changes in the voice due to changes in a person's physiology to create a range of measurements that provide early health detection and monitoring. www.sondehealth.com 

About Wellworks For You

 

Wellworks For You is a Corporate Wellness and Mental Well-Being Management Company, headquartered in Malvern, PA., focusing on high touch customer service. We provide customised wellness solutions for organisations throughout the world.

 

Press note - SHI CEO Thai Lee is an investor in Sonde Health.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 24 products and product candidates, including two that have been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

 

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

Contact:

Investors

 

EU media

 

US media

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.com

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

Stephanie Simon

+1 617 581 9333

stephanie@tenbridgecommunications.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAEAFXPEASEEEA
Date   Source Headline
21st May 202412:05 pmRNSPRTC's Vedanta Begins Phase 3 of VE303 in C. diff
20th May 20247:00 amRNSTender Offer
9th May 202412:05 pmRNSPRTC's Seaport Presents Ph1 and Ph2a SPT-300 Data
7th May 202412:05 pmRNSPRTC's Seaport Announces Board/Team Appointments
1st May 20247:00 amRNSTotal Voting Rights
25th Apr 20247:00 amRNSFinal Results
18th Apr 20247:00 amRNSNotice of Results
16th Apr 202412:00 pmRNSPRTC LYT-100 Ph2b in IPF Enrolled; Results Q4 2024
11th Apr 202412:00 pmRNSFDA Grants PRTC's LYT-200 Fast Track Designation
9th Apr 20247:00 amRNSPRTC Launches Seaport w/ $100M; Leadership Changes
19th Mar 20247:00 amRNS$100M Tender Offer
18th Mar 20241:32 pmRNS$14B Acquisition of PRTC’s Karuna by BMS Completed
13th Mar 202411:00 amRNSFDA Grants PRTC's LYT-200 Orphan Drug Designation
6th Mar 20247:00 amRNSPDMR Notification RSU Vesting
27th Feb 202412:00 pmRNSPRTC to Present at Cowen and Leerink Conferences
27th Feb 20247:00 amRNSPRTC: Akili Positive Ph3 & Japan PMDA Submission
8th Feb 20247:00 amRNSTransaction in Own Shares
7th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 20247:00 amRNSTransaction in Own Shares
5th Feb 20247:00 amRNSTransaction in Own Shares
2nd Feb 20247:00 amRNSTransaction in Own Shares
1st Feb 20247:00 amRNSTransaction in Own Shares
31st Jan 20247:00 amRNSTransaction in Own Shares
30th Jan 20247:00 amRNSTransaction in Own Shares
29th Jan 20245:30 pmRNSTransaction in Own Shares
26th Jan 20247:00 amRNSTransaction in Own Shares
25th Jan 20247:00 amRNSTransaction in Own Shares
24th Jan 20247:00 amRNSTransaction in Own Shares
23rd Jan 20247:00 amRNSTransaction in Own Shares
22nd Jan 20247:00 amRNSTransaction in Own Shares
19th Jan 20247:00 amRNSTransaction in Own Shares
18th Jan 20247:00 amRNSTransaction in Own Shares
17th Jan 20247:00 amRNSTransaction in Own Shares
16th Jan 20247:00 amRNSTransaction in Own Shares
15th Jan 20247:00 amRNSTransaction in Own Shares
12th Jan 20247:00 amRNSTransaction in Own Shares
11th Jan 20247:00 amRNSTransaction in Own Shares
10th Jan 20247:00 amRNSTransaction in Own Shares
9th Jan 20247:00 amRNSTransaction in Own Shares
8th Jan 20247:00 amRNSTransaction in Own Shares
5th Jan 20247:00 amRNSTransaction in Own Shares
4th Jan 20247:00 amRNSTransaction in Own Shares
3rd Jan 202412:00 pmRNSPureTech to present at the JP Morgan Conference
3rd Jan 20247:00 amRNSTransaction in Own Shares
27th Dec 20237:00 amRNSTransaction in Own Shares
22nd Dec 20231:31 pmRNSBMY Acquires PRTC Founded Entity Karuna for $14B
22nd Dec 20237:00 amRNSTransaction in Own Shares
21st Dec 20237:00 amRNSTransaction in Own Shares
20th Dec 20237:00 amRNSPRTC Year End Update & Outlook for 2024
20th Dec 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.